Discover how human-relevant models improve the understanding of drug delivery, efficacy, and safety of oligonucleotide therapies

New oligonucleotide-based modalities, such as small interfering RNA and antisense oligonucleotides, are improving treatment options for many diseases. Since these therapeutics have human-specific targets, the need for physiologically relevant Organ-on-a-chip models to assess drug delivery, efficacy, and safety continues to increase. In this webinar, Dr. Oliver Culley will explore how liver-on-a-chip technology enables researchers to delineate oligonucleotide delivery, distribution, uptake, and dosing to bridge the gap between preclinical studies and clinical success. 

Key Learning Objectives

• The development challenges of oligonucleotide therapeutics
• Examining the impact of N-acetylgalactosamine-conjugated oligonucleotides on gene expression using liver-on-a-chip models
• Real-world case studies on Liver-on-a-chip models in drug assessment

Speaker

Dr. Oliver Culley

Senior Scientist, CN Bio

Oliver is a Senior Scientist at CN Bio where his work focuses on modelling MASH in the PhysioMimix MPS system. Oliver completed a BSc (Hons) Biomedical Sciences at University of Manchester and a PhD in Cell Biology at King’s College London, before undertaking postdoctoral work in Bioengineering at Queen Mary University of London. With over 15 years’ experience in academia and industry, Oliver’s background is in Cell and Molecular Biology with a focus on high-content imaging and in vitro assay design